Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Marks & Spencer Launches Re:Spark to Ignite Renewable Electricity Adoption Across Its Fashion Supply Chain 19-11-2025, 21:59

VCI Global Announces Strategic Transformation to Become Regional Leader in AI Infrastructure, Stablecoin Payments, and Digital Asset Advisory 2-12-2025, 05:00